A retrospective cohort study suggests peak atrial longitudinal strain and peak atrial contraction strain could help clinicians identify HFpEF patients at greatest risk for developing atrial fibrillation.
TRANSLATE-HF is a collaborative effort between the AHA and AstraZeneca with the goal of increasing and optimizing SGLT2 inhibitor use in US patients. Hear further insight lead author from the first of 6 TRANSLATE-HF studies, which was presented at AHA 2020.
Data from the phase 3 SOLOIST-WHF and SCORED trials suggest sotagliflozin was associated with significant reductions in death from CVD in patients with worsening heart failure and significant reductions in blood glucose levels among patients with moderate to severe kidney impairment.
Professor John McMurray offers insight into a discussion he led at AHA 2020 exploring the notion that treatment of men and women with heart failure with preserved ejection fraction should be approached differently.
Results of a prospective, non-randomized trial indicate an approach using the HeartMate II LVAD combined with optimized medical therapy could increase the rate of device explantation and help facilitate cardiac remodeling.